Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics

blonca9
Feb 13, 2024
1 min read

Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN, highlights 72 week data Vera released in January, and discusses the potential path to market in this space.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight